Health

  • November 13, 2025

    CVS Reaches Deal In 'Non-Drowsy' Labeling Class Action

    A woman has agreed to settle her proposed class action against CVS Pharmacy accusing it of deceptively marketing its flu medicine as "non-drowsy" when it contained a drug known to cause drowsiness.

  • November 13, 2025

    Texas Court Says Landowner Doesn't Have To Sell $22M Plot

    A Texas Business Court judge ruled that a landowner doesn't have to go forward with a previously planned $22.5 million sale of 20.8 acres of land because the buyer terminated the deal.

  • November 13, 2025

    Donor Info Subpoena Chills Speech, Anti-Abortion Org Says

    An organization that operates anti-abortion pregnancy centers told the U.S. Supreme Court on Thursday that New Jersey is undermining its own subpoena power in a bid to avoid constitutional review of its request for information about the group's donors.

  • November 13, 2025

    Weight-Loss Drug MDL In Pa. Grows With 3 New Jersey Cases

    Three New Jersey cases were grouped into multidistrict litigation accusing Eli Lilly & Co. and Novo Nordisk of downplaying alleged side effects of weight loss drugs like Ozempic and Trulicity, according to a transfer order filed in Pennsylvania federal court.

  • November 13, 2025

    Maya Kowalski Fights Fla. Appeals Court's $213M Reversal

    The subject of the Netflix documentary "Take Care of Maya" has asked a Florida appeals court to reconsider its decision reversing a $213 million judgment, saying the court needs to clarify how far the immunity that state law grants to those who report possible child abuse extends.

  • November 13, 2025

    Fenwick, WilmerHale Steer $285M Mersana Take-Private Deal

    Pediatric cancer-focused biopharmaceutical company Day One Biopharmaceuticals, led by Fenwick & West LLP, announced plans Thursday to acquire clinical-stage biopharmaceutical company Mersana Therapeutics Inc., advised by WilmerHale, in a take-private deal worth up to $285 million.

  • November 13, 2025

    FTC Fails To Block Doctors' Testimony In $945M Merger Case

    A D.C. federal judge refused Thursday to bar a pair of outside doctors and consultants from vouching for Edwards Lifesciences Corp.'s planned JenaValve Technology Inc. acquisition, preferring to let the Federal Trade Commission contest their testimony in cross-examination and saying from the bench that he'll "make some popcorn."

  • November 13, 2025

    MVP: Foley & Lardner's Jason Mehta

    Jason Mehta, co-chair of Foley & Lardner LLP's healthcare litigation team, helped secure a bombshell ruling declaring parts of the False Claims Act unconstitutional and successfully defended COVID-19 test kit providers facing government investigations, earning him a spot as one of the 2025 Law360 Healthcare MVPs.

  • November 13, 2025

    Claims Firms Accused Of Misleading Plaintiffs In Pharma MDL

    A Pennsylvania federal judge has been asked to slow down aggressive marketing campaigns from claims recovery firms that are accused of using false and misleading advertising to attract plaintiffs in a multidistrict litigation action against pharmaceutical companies.

  • November 13, 2025

    DocGo Investors Seek OK Of $12.5M Deal Over Ex-CEO Claims

    Investors of mobile medical provider DocGo have asked a New York federal court to grant preliminary approval of their $12.5 million settlement of claims that the company deceived stockholders before a $432 million contract with New York City to provide emergency migrant housing came under public scrutiny.

  • November 13, 2025

    Virtua, Trinity Health Reach Deal Over $12M Legal Bill

    Virtua Health Inc. has reached a deal to settle its claims that Trinity Health Corp. backed out of an agreement to cover $12 million in counsel fees and costs incurred in a legal fight with a rival healthcare system, according to a New Jersey federal court order dismissing the suit with prejudice.

  • November 12, 2025

    Valsartan Cancer Expert Blocked, Ending First Injury Trial

    What was set to be the first bellwether case in the sprawling multidistrict litigation over contaminated blood pressure medication Valsartan was decided Monday when a New Jersey federal judge excluded as "pure speculation" the plaintiff's medical expert who testified that the drug caused a patient's liver cancer.

  • November 12, 2025

    Sandoz Tells 3rd Circ. To Restore Full $137M Win Over UTC

    Sandoz Inc. and its marketing firm RareGen LLC urged a Third Circuit panel on Wednesday to reinstate the full $137.2 million awarded in breach of contract damages against United Therapeutics Corp., claiming a lower court's decision to halve the damages provided a windfall to their adversary.

  • November 12, 2025

    NJ Justices Keep Ozempic Injury Mass Torts Separate

    The New Jersey Supreme Court has decided not to combine two Bergen County Superior Court mass tort cases over weight loss drugs including Ozempic, Wegovy and Mounjaro, keeping them separate based on the type of injury alleged.

  • November 12, 2025

    Judge Confirms $620K Award In Radiology Contract Dispute

    A Georgia federal judge on Wednesday upheld a $620,000 arbitration award in favor of an Indian teleradiology company against a radiology provider, rejecting the latter's bid to vacate the decision by claiming an arbitrator misinterpreted their long-standing services agreement.

  • November 12, 2025

    Fla. Lacked Evidence For Psychiatric Hold, Court Says

    A Florida appeals court on Wednesday reversed an involuntary commitment order after the state conceded its evidence was insufficient for a finding of mental illness under state law.

  • November 12, 2025

    1st Circ. Weighs Federal Halt To Planned Parenthood Funding

    First Circuit judges skeptically questioned a Planned Parenthood attorney Wednesday as they wrestled with whether Congress illegally singled out the organization in budget legislation that blocks its federal Medicaid funding for a year.

  • November 12, 2025

    Providence Health Nears ERISA Deal Over 401(k) Admin Costs

    Providence Health & Services has reached a tentative deal to resolve a proposed class action accusing the nonprofit healthcare system of misspending millions of dollars in forfeited employer retirement contributions in violation of federal benefits law, the parties told a Seattle federal judge.

  • November 12, 2025

    Judge Questions Cigna Site Users' Standing In Data Suit

    A Pennsylvania federal judge suggested Wednesday that she may toss a proposed class action alleging Cigna failed to safeguard private health data by tracking plan members' website usage in violation of state wiretapping and federal privacy laws, ordering the plaintiffs to demonstrate that they have standing to sue.

  • November 12, 2025

    MVP: Bass Berry's Michael Hess

    Michael Hess of Bass Berry & Sims PLC represented private equity firm Sycamore Partners in its roughly $24 billion deal taking Walgreens off the public market, earning him a spot among the 2025 Law360 Healthcare MVPs.

  • November 12, 2025

    Judge Won't Halt Injunction Blocking Trump's Trans Care Ban

    A Washington federal judge rejected the Trump administration's bid to halt a temporary injunction, saying the president took too long to request a pause in the order, which blocks federal officials from withholding federal healthcare funds to hospitals in four states that provide gender-affirming care. 

  • November 12, 2025

    Fired Vax Refuser Hits Kaiser With Religious Bias Suit

    A Kaiser unit care manager was unlawfully terminated after being wrongfully denied a religious exemption to its policy requiring COVID-19 vaccinations, she told a Georgia federal court.

  • November 12, 2025

    Georgia Says Trans Prisoner Care Ban 'Clearly Passes Muster'

    Georgia called for a federal judge to toss a legal challenge to its new law revoking funding for gender-affirming healthcare in state prisons, arguing Monday that cutting off support for hormone therapy is the sort of "quintessentially permissible" decision afforded to lawmakers by the U.S. Supreme Court.

  • November 12, 2025

    Proposed Class Fights P&G Attempt To Transfer Tampon Case

    A proposed class alleging that Procter & Gamble tampons contain unsafe amounts of lead is urging a California federal court to reject the company's bid to transfer the case to Ohio federal court.

  • November 10, 2025

    Law360 MVP Awards Go To Top Attorneys From 76 Firms

    The attorneys chosen as Law360's 2025 MVPs have distinguished themselves from their peers by securing significant achievements in high-stakes litigation, complex global matters and record-breaking deals.

Expert Analysis

  • Agentic AI Puts A New Twist On Attorney Ethics Obligations

    Author Photo

    As lawyers increasingly use autonomous artificial intelligence agents, disciplinary authorities must decide whether attorney responsibility for an AI-caused legal ethics violation is personal or supervisory, and firms must enact strong policies regarding agentic AI use and supervision, says Grace Wynn at HWG.

  • When AI Denies, Insurance Bad Faith Claims May Follow

    Author Photo

    Two recent rulings from Minnesota and Kentucky federal courts signal that past statements about claims-handling practices may leave insurers using artificial intelligence programs in claims administration vulnerable to suits alleging bad faith and unfair trade practices, say attorneys at Cozen O'Connor.

  • Health Insurance Kickback Cases Signal Greater Gov't Focus

    Author Photo

    A series of recent indictments by federal prosecutors in California suggests that the Eliminating Kickbacks in Recovery Act is gaining momentum as an enforcement tool against illegal inducement of patient referrals in the realm of commercial health insurance, say attorneys at BakerHostetler.

  • FDA Transparency Plans Raise Investor Disclosure Red Flags

    Author Photo

    The U.S. Food and Drug Administration’s recently announced intent to publish complete response letters for unapproved drugs and devices implicates certain investor disclosure requirements under securities laws, making it necessary for life sciences and biotech companies to adopt robust controls going forward, say attorneys at Arnold & Porter.

  • Series

    Being A Professional Wrestler Makes Me A Better Lawyer

    Author Photo

    Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability.

  • Series

    Law School's Missed Lessons: Adapting To The Age Of AI

    Author Photo

    Though law school may not have specifically taught us how to use generative artificial intelligence to help with our daily legal tasks, it did provide us the mental building blocks necessary for adapting to this new technology — and the judgment to discern what shouldn’t be automated, says Pamela Dorian at Cozen O'Connor.

  • Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning

    Author Photo

    A recent Texas bankruptcy court decision that a postconfirmation litigation trust has no obligations to repay a completely drawn down $2 million litigation funding agreement serves as a warning for estate administrators and funders to properly disclose the intended financing, say attorneys at Kleinberg Kaplan.

  • DOJ's Novel Cybersecurity FCA Case Is A Warning To Medtech

    Author Photo

    The U.S. Department of Justice's recent False Claims Act settlement with Illumina over alleged cybersecurity deficiencies suggests that enforcement agencies and whistleblowers are focusing attention toward cybersecurity in life sciences and medical tech, but also reveals key unanswered questions about the legal viability of such allegations, say attorneys at Morgan Lewis.

  • Demystifying The Civil Procedure Rules Amendment Process

    Author Photo

    Every year, an advisory committee receives dozens of proposals to amend the Federal Rules of Civil Procedure, most of which are never adopted — but a few pointers can help maximize the likelihood that an amendment will be adopted, says Josh Gardner at DLA Piper.

  • With Obligor Ruling, Ohio Justices Calm Lending Waters

    Author Photo

    A recent decision by the Ohio Supreme Court, affirming a fundamental principle that lenders have no duty to disclose material risks to obligors, provides clarity for commercial lending practices in Ohio and beyond, and offers a reminder of the risks presented by guarantee arrangements, says Carrie Brosius at Vorys.

  • How 2nd Circ. Cannabis Ruling Upends NY Licensing

    Author Photo

    A recent Second Circuit decision in Variscite NY Four v. New York, holding that New York's extra-priority cannabis licensing preference for applicants with in-state marijuana convictions violates the dormant commerce clause, underscores that state-legal cannabis markets remain subject to the same constitutional constraints as other economic markets, say attorneys at Harris Beach.

  • Parenting Skills That Can Help Lawyers Thrive Professionally

    Author Photo

    As kids head back to school, the time is ripe for lawyers who are parents to consider how they can incorporate their parenting skills to build a deep, meaningful and sustainable legal practice, say attorneys at Alston & Bird.

  • Series

    Teaching Trial Advocacy Makes Us Better Lawyers

    Author Photo

    Teaching trial advocacy skills to other lawyers makes us better litigators because it makes us question our default methods, connect to young attorneys with new perspectives and focus on the needs of the real people at the heart of every trial, say Reuben Guttman, Veronica Finkelstein and Joleen Youngers.

  • Federal AI Action Plan Marks A Shift For Health And Bio Fields

    Author Photo

    The Trump administration's recent artificial intelligence action plan significantly expands federal commitments across biomedical agencies, defining a pivotal moment for attorneys and others involved in research collaborations, managing regulatory compliance and AI-related intellectual property, says Mehrin Masud-Elias at Arnold & Porter.

  • Preparing For DEA Rescheduling Of 2 Research Chemicals

    Author Photo

    A recent decision to allow the U.S. Drug Enforcement Administration to reclassify two research psychedelics in Schedule I under the Controlled Substances Act may pose significant barriers to scientific study, including stringent registration requirements, heightened security protocols and burdensome reporting obligations, say Kimberly Chew at Husch Blackwell and Jackie von Salm at Psilera.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.